PainReform Provides Further Update on Manufacturing of PRF-110
TEL AVIV, Israel, Nov. 8, 2022 (GLOBE NEWSWIRE) — PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a further update related to the manufacturing process of clinical batches for PRF-110. Ilan Hadar, Chief Executive Officer of Pain Reform, stated, “As previously announced, […]
PainReform Provides PRF-110 Manufacturing Update
Completed tech transfer to CMO resulting in new process improvements On track to commence Phase 3 clinical trial in bunionectomy in November 2022 Tel Aviv, Israel – October 4, 2022 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided an update […]
PainReform to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Tel Aviv, Israel – September 1, 2022 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform, will be presenting at the H.C. Wainwright 24th Annual Global Investment Conference which is being held September […]
PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification
Tel Aviv, Israel, August 16, 2022 —PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that the Company received a letter from the Nasdaq Listing Qualifications (the “Letter”), indicating that the Company is not in compliance with the minimum bid price requirement […]
PainReform Provides Business Update for the Second Quarter of 2022
On track to commence Phase 3 clinical trial in bunionectomy in the fourth quarter of 2022 Completes tech transfer to CMO for manufacturing of clinical batches Tel Aviv, Israel – August 16, 2022 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today […]
PainReform Provides Business Update for the First Quarter of 2022
Reports successful batch manufacturing of PRF-110 and continued progress towards commencing Phase 3 clinical trials in the second half of 2022 Tel Aviv, Israel – May 17, 2022 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company“), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, yesterday provided a business update for […]
PainReform to Present at The Noble Capital Markets’ Eighteenth Annual Investor Conference on April 20th
TEL AVIV, Israel, – April 12, 2022 – PainReform Ltd. (Nasdaq: PRFX), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced that Ilan Hadar, Chief Executive Officer of PainReform will present at the Noble Capital Markets’ Eighteenth Annual Investor Conference being held on April 20-21, 2022 at the Hard Rock […]
PainReform to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest onMarch 28th – 30th
Tel Aviv, Israel – March 21, 2022 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today announced it will present at the 2022 Virtual Growth Conference, presented by Maxim Group LLC and hosted by M-Vest, on March 28th – 30th from 9:00 […]
PainReform Provides Year-End Business Update; On track to Commence Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief in the Second Half of 2022
Tel Aviv, Israel – March 17, 2022 – PainReform Ltd. (Nasdaq: PRFX) (“PainReform” or the “Company”), a clinical-stage specialty pharmaceutical company focused on the reformulation of established therapeutics, today provided a business update for the year ended December 31, 2021. Ilan Hadar, Chief Executive Officer, stated, “We remain on track to commence our Phase 3 […]
